Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Tykerb
Active Ingredient: Lapatinib ditosilate 405mg equivalent to 250mg Lapatinib free base
Dosage Form: Tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, United Kingdom
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 17th day of August 2007.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).